Notably, Klk1 treatment suppressed these pro‐tumorigenic changes, while the B1R antagonist SSR240612 reversed this effect, highlighting the KLK1‐B1R axis as a potential therapeutic target for inflammation‐associated colorectal cancer. The gene discussed is BDKRB1; the disease is colorectal cancer.